Koda-KimbleMARotblattMD. Diabetes mellitus. In: KatcherBSYoungLYKoda-KimbleMA, eds. Applied therapeutics: The clinical use of drugs. Spokane: Applied Therapeutics, Inc., 1983: 1335–1414.
2.
RootMAChanceREGallowayJA. Immunogenicity of insulin. Diabetes1972; 22 (suppl 2): 657–60.
3.
BersonSAYalowRS. Insulin in blood and insulin antibodies. Am J Med1966; 40: 676–90.
4.
FiremanPFinebergSEGallowayJA. Development of IgE antibodies to human (recombinant DNA), porcine, and bovine insulins in diabetic subjects. Diabetes Care1982; 5 (suppl 2): 119–25.
5.
SchernthanerGBorkensteinMFinkM. Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR-typed insulin-dependent diabetic individuals. Diabetes Care1983; 6 (suppl 1): 43–8.
6.
TeuscherA. The place of monocomponent insulins in the therapy of diabetes mellitus. Schweiz Med Wochenschr1975; 105: 485–94.
7.
KorpWLevettRE. Experiences with monocomponent insulin. Wein Klin Wochenschr1973: 85: 326–30.
8.
KahnCRRosenthalAS. Immunologic reactions to insulin: Insulin allergy, insulin resistance, and the autoimmune insulin syndrome. Diabetes Care1979; 2: 283–95.
9.
TeuscherA. Treatment of Insulin lipoatrophy with monocomponent insulin. Diabetologia1974; 10: 211–4.
10.
SkylerJS. A plethora of insulins. Diabetes Care1980; 3: 638–9.
11.
HomePDAlbertiKGMM. The new insulins: Their characteristics and clinical indications. Drugs1982; 24: 401–13.
GallowayJABresslerR. Insulin treatment in diabetes. Med Clin North Am1978; 62: 663–80.
14.
JohnsonIS. Authenticity and purity of human insulin (recombinant DNA). Diabetes Care1982; 5 (suppl 2): 4–12.
15.
MarkussenJDamgaardUPingelMSnelLSorensenARSorensenE. Human insulin (Novo): Chemistry and characteristics. Diabetes Care1983; 6 (suppl 1): 4–8.
16.
SkylerJS. Human insulin of recombinant DNA origin: Clinical potential. Diabetes Care1982; 5 (suppl 2): 181–6.
17.
GallowayJARootMABergstromR. Clinical pharmacologic studies with human insulin (recombinant DNA). Diabetes Care1982; 5 (suppl 2): 13–22.
18.
EbiharaAKondoKOhashiKKoshakaKKuzuyaTTaruiS. Clinical Pharmacology of human insulin of recombinant DNA origin in healthy volunteers. Diabetes Care1982; 5 (suppl 2): 35–8.
19.
LandgrafRKammererSBockT. Crossover study with human insulin (recombinant DNA) in type I diabetic subjects. Diabetes Care1982; 5 (suppl 2): 39–42.
20.
HoweyDCFinebergSENolenPA. The therapeutic efficacy of human insulin (recombinant DNA) in patients with insulin-dependent diabetes mellitus: A comparative study with purified pork insulin. Diabetes Care1982; 5 (suppl 2): 73–7.
21.
BottermanPGyaramHWahlKErmlerRLebenderM. Insulin concentrations and time-action profiles of three different intermediate acting insulin preparations in non-diabetic volunteers under glucose-controlled infusion technique. Diabetes Care1982; 5 (suppl 2): 43–52.
22.
MirouzeJMonnierLRichardJLGancelASovaKB. Comparative study of NPH human insulin (recombinant DNA) and pork insulin in diabetic subjects: Preliminary report. Diabetes Care1982; 5 (suppl 2): 60–2.
23.
MarreMTabbi-AnneniATabbi-AnneniHAssanR. Comparative study of NPH human insulin (recombinant DNA) and NPH bovine insulin in diabetic subjects. Diabetes Care1982; 5 (suppl 2): 63–6.
24.
KemmerFWSonnenbergGCuppersHJBergerM. Absorption kinetics of semisynthetic human insulin and biosynthetic (recombinant DNA) human insulin. Diabetes Care1982; 5 (suppl 2): 23–8.
25.
FinebergSEGallowayJAFinebergNSRathburnMJ. Immunologic improvement resulting from the transfer of animal insulin-treated diabetic subjects to human insulin (recombinant DNA). Diabetes Care1982; 5 (suppl 2): 107–13.
26.
SchernthanerG. Affinity of IgG-insulin antibodies to human (recombinant DNA) insulin and porcine insulin in insulin-treated diabetic individuals with and without insulin resistance. Diabetes Care1982; 5 (suppl 2): 114–8.
27.
VelcovskyHGFederlinKF. Insulin-specific IgG and IgE antibody response in type I diabetic subjects exclusively treated with human insulin (recombinant DNA). Diabetes Care1982; 5 (suppl 2): 126–8.
28.
BachmannWHascheHMehnertH. Intradermal desensitization with human insulin (recombinant DNA) in a patient with severe allergic skin reaction to insulin. Diabetes Care1982; 5 (suppl 2): 165–7.
29.
DeLeeuwIDelvigneCBekaertJ. Insulin allergy treated with human insulin (recombinant DNA). Diabetes Care1982; 5 (suppl 2): 168–70.
30.
ManeschiFFinebergSEKohnerEM. Successful treatment of immune-mediated insulin resistance by human insulin (recombinant DNA). Diabetes Care1982; 5 (suppl 2): 175–9.
31.
HomePDSheperdGAANoyG. Comparison of the activity and pharmacokinetics of porcine insulin and human insulin (Novo) as assessed by the glucose clamp technique in normal and diabetic man. Diabetes Care1983; 6 (suppl 2): 23–8.
32.
MirouzeJBenghernaoutOPhamTCRichardJLBringerJ. Comparative analysis of soluble porcine and human insulin (Novo) using the artificial pancreas. Diabetes Care1983; 6 (suppl 1): 40–2.
33.
CharlesMASzekeresAStatenMWorcesterBWalshK. Comparison of porcine insulin and human insulin (Novo) using glucose-controlled insulin infusion system, glucose-insulin dose response curves, and the outpatient use of human insulin (Novo) in insulin-dependent diabetes. Diabetes Care1983; 6 (suppl 1): 29–34.
34.
EbiharaAKondoKOhashiKKosakaKKuzuyaTMatsudaA. Comparative clinical pharmacology of human insulin (Novo) and porcine insulin in normal subjects. Diabetes Care1983; 6 (suppl 1): 17–22.
35.
SonnenbergGECuppersHJBergerM. Subcutaneous use of regular human insulin (Novo): Pharmacokinetics and continuous insulin infusion therapy. Diabetes Care1983; 6 (suppl 1): 35–9.
36.
FalholtKHoskamAMKaramanosBGSusstrunkHViswanathanMHedingLG. Insulin-specific IgE in serum of 67 diabetic patients against human insulin (Novo), porcine insulin, and bovine insulin. Four case reports. Diabetes Care1983; 6 (suppl 1): 61–5.
